Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Genentech Fully Supports Efforts to Increase Transparency

Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.

We believe the partnership between the medical community and companies like ours who discover and develop medicines is critically important to our shared goals of advancing scientific knowledge and delivering new medicines to patients in need.

Our ability to engage with doctors, researchers and opinion leaders in robust dialogue on approved and investigational medicines is vital to our research and development efforts. These external experts also lead the clinical trials evaluating the safety and efficacy of our medicines, and provide critical information and insight into patient needs.

Sunshine Act Compliance

The Sunshine Act, a.k.a. the National Physician Payment Transparency Program (Open Payments), is a section of the Patient Protection and Affordable Care Act of 2010. It requires pharmaceutical and medical device companies report certain payments to the Federal government.

Genentech is committed to ensuring that the Sunshine Act data we report is as accurate as possible, and we employed extensive processes to collect and review the data prior to submission.

We are also committed to providing healthcare professionals with the information they need to accurately track their Sunshine-reportable payments. If you have questions, please contact [email protected]